News

Cefdinir for Oral Suspension Recalled

06/06/2019

Lupin Pharmaceuticals Inc. is recalling a single lot of 60-mL bottles of cefdinir for oral suspension, 250 mg/5 mL (NDC 68180-723-20), after a customer found a piece of metal in the powder prior to reconstitution. The recall appeared in the June 5, 2019, US Food and Drug Administration (FDA) Enforcement Report.

The recall affects 18,408 bottles containing cefdinir powder for oral suspension from lot F802335 (Exp. 11/20). The bottles were distributed throughout the United States.

Lupin Pharmaceuticals voluntarily initiated the recall May 23, 2019. On May 30, 2019, the FDA designated the recall Class II, communicating use of the drug may cause temporary or medically reversible adverse health consequences or a remote possibility of serious harm.

Cefdinir is a prescription antibiotic used to treat a variety of bacterial infections.

—Jolynn Tumolo

Stay Informed & Sign Up Today

Pharmacy Learning Network Newsletter

Video Insights

Videos

David Rubin, MD, on JAK Inhibitors: Small But Mighty

11/22/2023

Featuring David Rubin, MD

Dr Rubin reviews his presentation from the Advances in Inflammatory Bowel Disease regional meeting on the latest information on the safety and efficacy of Janus kinase inhibitors for the treatment of inflammatory bowel disease.

Dr Rubin reviews his...

11/22/2023

Pharmacy Learning Network

Videos

Advantages and Drawbacks of Lecanemab in Alzheimer Disease Treatment

11/10/2023

Featuring Paul Schulz, MD

Dr Shulz discusses the FDA-approved lecanemab for the treatment of AD.

Dr Shulz discusses the...

11/10/2023

Pharmacy Learning Network

Videos

Immunosuppressants or Immunomodulators? Biologic Agents for Psoriasis

10/27/2023

Featuring Ronald Vender, MD, FRCPC

Featuring Ronald Vender, MD, FRCPC ...

In this exclusive interview, Dr Ronald Vender goes over the highly effective targeted biologic therapies used to treat psoriasis.

In this exclusive interview, Dr...

10/27/2023

Pharmacy Learning Network

Videos

Application of Dupilumab to Pediatric Patients With Atopic Dermatitis

10/27/2023

Featuring Abigail Cline, MD, PhD, FAAD

Featuring Abigail Cline, MD, PhD, FAA...

In this feature video, Dr Abigail Cline discusses current literature to assess reported efficacies, side effects, and risks of using dupilumab to treat atopic dermatitis in pediatric patients.

In this feature video, Dr...

10/27/2023

Pharmacy Learning Network

Videos

Patient Considerations When Prescribing Lecanemab for Alzheimer Disease

10/06/2023

Featuring Paul Schulz, MD

Dr Paul Schulz discusses the newly FDA-approved lecanemab for the treatment of AD.

Dr Paul Schulz discusses the...

10/06/2023

Pharmacy Learning Network

Headshots of Chris Fausel, PharmD, MHA, BCOP; Erin Hamai Tom, PharmD, APh, MBA, BCACP; and Ryan Nix, PharmD, MMHC

Videos

Specialty Pharmacy Next: Focus on Distribution Processes, Data Utilization, New Drugs, and More

07/18/2023

Featuring Chris Fausel, PharmD, MHA, BCOP; Erin Hamai Tom, PharmD, APh, MBA, BCACP; and Ryan Nix, PharmD, MMHC

Featuring Chris Fausel, PharmD, MHA, ...

In this roundtable, cochairs of Specialty Pharmacy Next gather to discuss pertinent topics on the agenda such as white and brown bagging practices and data usage for program growth, as well as who may benefit most from attending the meeting.

In this roundtable, cochairs of...

07/18/2023

Pharmacy Learning Network

Videos

Leaders in Pharmacy Come Together to Discuss and Debate Oncology-Related Developments

06/28/2021

Julie Gould

Chris Fausel, PharmD, Val Adams, PharmD, Kirollos Hanna, PharmD, and Lisa Holle, PharmD, cochairs of Great Debates and Updates Oncology Pharmacy, come together to discuss this new CPE event aimed at educating pharmacists interested in...

Chris Fausel, PharmD, Val Adams,...

06/28/2021

Pharmacy Learning Network

Videos

Expanded FDA Approval Improves Care Access, Rates of Flu Cases

04/19/2021

Gregg Sylvester, MD, MPH, chief medical officer, and David Ross, vice president, commercial operations for North America, both at Seqirus, discuss the recent FDA approval for Flucelvax Quadrivalent, explain what the expanded indication means...

Gregg Sylvester, MD, MPH, chief...

04/19/2021

Pharmacy Learning Network

Videos

Identifying Drug Diversion Differences in Retail Pharmacies Compared With Health Systems

12/28/2020

Tom Knight, founder and CEO, Invistics, identifies drug diversion differences in a hospital or health system versus a retail pharmacy, and explains what retail pharmacies can do to better detect and address drug diversion.

Tom Knight, founder and CEO,...

12/28/2020

Pharmacy Learning Network

Videos

Identifying Risks of Human Error, Workarounds in Pharmacy

12/22/2020

Matthew Grissinger, RPh, FISMP, FASCP, director of Error Reporting Programs, Institute for Safe Medication Practices, discusses how human error, various at-risk behaviors, as well as workarounds taken by staff members all impact outcomes and...

Matthew Grissinger, RPh, FISMP,...

12/22/2020

Pharmacy Learning Network

Cefdinir for Oral Suspension Recalled

Stay Informed & Sign Up Today

Video Insights

Specialties

Events

Year Round Education

HMP Global Products